Methyl 3-acetamido-5-nitrothiophene-2-carboxylate, 97%, 10g

6-Bromo-2-quinazolinamine, 95.0%, 1g

2-Thiophenemethylamine, 95.0%, 5g

1-(7,8-Diamino-1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-2,2,2-trifluoroethanone, 98%, 5g

2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-cyclohexylacetic acid, 97%, 1g

2-Chloro-3-nitro-5-(trifluoromethyl)benzamide, 98%, 1g

2-Hydroxy-5-nitronicotinic acid, 96.0%, 1g

1-(1-Bromoethyl)-4-fluorobenzene, 95.0%, 10g

4-(2-Methoxyethyl)phenol>98.0%(GC)25g

5-(4-Bromo-2-(trifluoromethyl)phenyl)oxazole, 98%, 1g

8-Bromo-2-methyl-3,4-dihydro-2H-1,4-benzoxazine, 97%, 250mg

(2E)-1-(2-chlorophenyl)-3-(2-methylphenyl)prop-2-en-1-one, 95.0%, 10g

Trial kit Spectra/Por® Biotech CE, 100–500 dalton(s), 1 Piece(s)